Exact Mass: 471.15426160000004
Exact Mass Matches: 471.15426160000004
Found 298 metabolites which its exact mass value is equals to given mass value 471.15426160000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
10-Formyldihydrofolate
10-Formyldihydrofolate is a folate compound that has not been found as a component of intracellular folates in normal tissues but has been identified in the cytosol of methotrexate (MTX)-treated MCF-7 breast cancer cells and normal human myeloid precursor cells. The origin of 10-formyldihydrofolate remains an enigma. Its appearance only in the extracts from MTX-treated cells is not consistent with a simple oxidation of lO-formyl-H4folate during the extraction procedure. This, however, does not exclude the occurrence of spontaneous oxidation of 10-formyl-H4folate within the intact cells prior to the folate extraction. (PMID: 3366769) [HMDB] 10-formyldihydrofolate is a folate compound that has not been found as a component of intracellular folates in normal tissues but has been identified in the cytosol of methotrexate (MTX)-treated MCF-7 breast cancer cells and normal human myeloid precursor cells. The origin of 10-formyldihydrofolate remains an enigma. Its appearance only in the extracts from MTX-treated cells is not consistent with a simple oxidation of lO-formyl-H4folate during the extraction procedure. This, however, does not exclude the occurrence of spontaneous oxidation of 10-formyl-H4folate within the intact cells prior to the folate extraction. (PMID: 3366769).
Dabigatran
C25H25N7O3 (471.20187799999997)
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173066 - Direct Thrombin Inhibitor D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Hydroxydesmthyl doxepin glucuronide
Hydroxydesmthyl doxepin glucuronide is a metabolite of doxepin. Doxepin is a psychotropic agent with tricyclic antidepressant and anxiolytic properties, known under many brand-names such as Aponal, the original preparation by Boehringer-Mannheim, now part of the Roche group; Adapine, Doxal, Deptran, Sinquan and Sinequan. As doxepin hydrochloride, it is the active ingredient in cream-based preparations (Zonalon and Xepin) for the treatment of dermatological itch. (Wikipedia)
Norfluoxetine glucuronide
Norfluoxetine glucuronide is a metabolite of fluoxetine. Fluoxetine (also known by the tradenames Prozac, Sarafem, Fontex, among others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company. It was presented to the U.S. Food and Drug Administration in February 1977, with Eli Lilly receiving final approval to market the drug in December 1987. Fluoxetine went off-patent in August 2001 (Wikipedia).
2-Naphthalenecarboxamide, 3-hydroxy-4-[(4-methyl-2-nitrophenyl)azo]-N-(3-nitrophenyl)-
N-(4-(2-(2,3-Dihydrobenzo(b)furan-7-carboxamido)ethyl)benzenesulfonyl)-N'-cyclohexylurea
C24H29N3O5S (471.18278240000006)
Dabigatran
C25H25N7O3 (471.20187799999997)
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173066 - Direct Thrombin Inhibitor D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid
C27H34ClNO2S (471.1998654000001)
D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors
5-formyl-tetrahydrofolate
5-formyl-tetrahydrofolate is a member of the class of compounds known as tetrahydrofolic acids. Tetrahydrofolic acids are heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with at least one L-glutamic acid unit. 5-formyl-tetrahydrofolate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 5-formyl-tetrahydrofolate can be found in a number of food items such as fennel, greenthread tea, orange mint, and coriander, which makes 5-formyl-tetrahydrofolate a potential biomarker for the consumption of these food products.
4-hydroxy-3-methoxyphenylacetonitrile 4-O-alpha-L-rhamnopyranosyl(1->6)-beta-D-glucopyranoside|adenophoraside C
C21H29NO11 (471.17405240000005)
N13-(1-L-rhamnosyl)arcyriaflavin A
C26H21N3O6 (471.14302860000004)
aristolactam-N-beta-D-glucopyranoside|aristolactam-N-beta-D-glucoside|Aristolactam-N-??-D-glucoside
CAY10650
CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion[1][2].
Pemetrexed
C20H19N5Na2O6 (471.11306740000003)
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C471 - Enzyme Inhibitor > C2021 - Thymidylate Synthase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000970 - Antineoplastic Agents
1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]
C27H34ClNO2S (471.1998654000001)
Ala His Met Asn
C18H29N7O6S (471.18999340000005)
Ala His Asn Met
C18H29N7O6S (471.18999340000005)
Ala Met His Asn
C18H29N7O6S (471.18999340000005)
Ala Met Asn His
C18H29N7O6S (471.18999340000005)
Ala Asn His Met
C18H29N7O6S (471.18999340000005)
Ala Asn Met His
C18H29N7O6S (471.18999340000005)
Cys Gly His Arg
C17H29N9O5S (471.20122640000005)
Cys Gly Arg His
C17H29N9O5S (471.20122640000005)
Cys His Gly Arg
C17H29N9O5S (471.20122640000005)
Cys His Asn Val
C18H29N7O6S (471.18999340000005)
Cys His Arg Gly
C17H29N9O5S (471.20122640000005)
Cys His Val Asn
C18H29N7O6S (471.18999340000005)
Cys Asn His Val
C18H29N7O6S (471.18999340000005)
Cys Asn Val His
C18H29N7O6S (471.18999340000005)
Cys Arg Gly His
C17H29N9O5S (471.20122640000005)
Cys Arg His Gly
C17H29N9O5S (471.20122640000005)
Cys Val His Asn
C18H29N7O6S (471.18999340000005)
Cys Val Asn His
C18H29N7O6S (471.18999340000005)
Asp His Asn Ser
C17H25N7O9 (471.17136800000003)
Asp His Ser Asn
C17H25N7O9 (471.17136800000003)
Asp Asn His Ser
C17H25N7O9 (471.17136800000003)
Asp Asn Ser His
C17H25N7O9 (471.17136800000003)
Asp Ser His Asn
C17H25N7O9 (471.17136800000003)
Asp Ser Asn His
C17H25N7O9 (471.17136800000003)
Gly Cys His Arg
C17H29N9O5S (471.20122640000005)
Gly Cys Arg His
C17H29N9O5S (471.20122640000005)
Gly His Cys Arg
C17H29N9O5S (471.20122640000005)
Gly His Met Gln
C18H29N7O6S (471.18999340000005)
Gly His Gln Met
C18H29N7O6S (471.18999340000005)
Gly His Arg Cys
C17H29N9O5S (471.20122640000005)
Gly Met His Gln
C18H29N7O6S (471.18999340000005)
Gly Met Gln His
C18H29N7O6S (471.18999340000005)
Gly Gln His Met
C18H29N7O6S (471.18999340000005)
Gly Gln Met His
C18H29N7O6S (471.18999340000005)
Gly Arg Cys His
C17H29N9O5S (471.20122640000005)
Gly Arg His Cys
C17H29N9O5S (471.20122640000005)
His Ala Met Asn
C18H29N7O6S (471.18999340000005)
His Ala Asn Met
C18H29N7O6S (471.18999340000005)
His Cys Gly Arg
C17H29N9O5S (471.20122640000005)
His Cys Asn Val
C18H29N7O6S (471.18999340000005)
His Cys Arg Gly
C17H29N9O5S (471.20122640000005)
His Cys Val Asn
C18H29N7O6S (471.18999340000005)
His Asp Asn Ser
C17H25N7O9 (471.17136800000003)
His Asp Ser Asn
C17H25N7O9 (471.17136800000003)
His Gly Cys Arg
C17H29N9O5S (471.20122640000005)
His Gly Met Gln
C18H29N7O6S (471.18999340000005)
His Gly Gln Met
C18H29N7O6S (471.18999340000005)
His Gly Arg Cys
C17H29N9O5S (471.20122640000005)
His Met Ala Asn
C18H29N7O6S (471.18999340000005)
His Met Gly Gln
C18H29N7O6S (471.18999340000005)
His Met Asn Ala
C18H29N7O6S (471.18999340000005)
His Met Gln Gly
C18H29N7O6S (471.18999340000005)
His Asn Ala Met
C18H29N7O6S (471.18999340000005)
His Asn Cys Val
C18H29N7O6S (471.18999340000005)
His Asn Asp Ser
C17H25N7O9 (471.17136800000003)
His Asn Met Ala
C18H29N7O6S (471.18999340000005)
His Asn Ser Asp
C17H25N7O9 (471.17136800000003)
His Asn Val Cys
C18H29N7O6S (471.18999340000005)
His Gln Gly Met
C18H29N7O6S (471.18999340000005)
His Gln Met Gly
C18H29N7O6S (471.18999340000005)
His Arg Cys Gly
C17H29N9O5S (471.20122640000005)
His Arg Gly Cys
C17H29N9O5S (471.20122640000005)
His Ser Asp Asn
C17H25N7O9 (471.17136800000003)
His Ser Asn Asp
C17H25N7O9 (471.17136800000003)
His Val Cys Asn
C18H29N7O6S (471.18999340000005)
His Val Asn Cys
C18H29N7O6S (471.18999340000005)
Met Ala His Asn
C18H29N7O6S (471.18999340000005)
Met Ala Asn His
C18H29N7O6S (471.18999340000005)
Met Gly His Gln
C18H29N7O6S (471.18999340000005)
Met Gly Gln His
C18H29N7O6S (471.18999340000005)
Met His Ala Asn
C18H29N7O6S (471.18999340000005)
Met His Gly Gln
C18H29N7O6S (471.18999340000005)
Met His Asn Ala
C18H29N7O6S (471.18999340000005)
Met His Gln Gly
C18H29N7O6S (471.18999340000005)
Met Asn Ala His
C18H29N7O6S (471.18999340000005)
Met Asn His Ala
C18H29N7O6S (471.18999340000005)
Met Gln Gly His
C18H29N7O6S (471.18999340000005)
Met Gln His Gly
C18H29N7O6S (471.18999340000005)
Asn Ala His Met
C18H29N7O6S (471.18999340000005)
Asn Ala Met His
C18H29N7O6S (471.18999340000005)
Asn Cys His Val
C18H29N7O6S (471.18999340000005)
Asn Cys Val His
C18H29N7O6S (471.18999340000005)
Asn Asp His Ser
C17H25N7O9 (471.17136800000003)
Asn Asp Ser His
C17H25N7O9 (471.17136800000003)
Asn His Ala Met
C18H29N7O6S (471.18999340000005)
Asn His Cys Val
C18H29N7O6S (471.18999340000005)
Asn His Asp Ser
C17H25N7O9 (471.17136800000003)
Asn His Met Ala
C18H29N7O6S (471.18999340000005)
Asn His Ser Asp
C17H25N7O9 (471.17136800000003)
Asn His Val Cys
C18H29N7O6S (471.18999340000005)
Asn Met Ala His
C18H29N7O6S (471.18999340000005)
Asn Met His Ala
C18H29N7O6S (471.18999340000005)
Asn Ser Asp His
C17H25N7O9 (471.17136800000003)
Asn Ser His Asp
C17H25N7O9 (471.17136800000003)
Asn Val Cys His
C18H29N7O6S (471.18999340000005)
Asn Val His Cys
C18H29N7O6S (471.18999340000005)
Gln Gly His Met
C18H29N7O6S (471.18999340000005)
Gln Gly Met His
C18H29N7O6S (471.18999340000005)
Gln His Gly Met
C18H29N7O6S (471.18999340000005)
Gln His Met Gly
C18H29N7O6S (471.18999340000005)
Gln Met Gly His
C18H29N7O6S (471.18999340000005)
Gln Met His Gly
C18H29N7O6S (471.18999340000005)
Arg Cys Gly His
C17H29N9O5S (471.20122640000005)
Arg Cys His Gly
C17H29N9O5S (471.20122640000005)
Arg Gly Cys His
C17H29N9O5S (471.20122640000005)
Arg Gly His Cys
C17H29N9O5S (471.20122640000005)
Arg His Cys Gly
C17H29N9O5S (471.20122640000005)
Arg His Gly Cys
C17H29N9O5S (471.20122640000005)
Ser Asp His Asn
C17H25N7O9 (471.17136800000003)
Ser Asp Asn His
C17H25N7O9 (471.17136800000003)
Ser His Asp Asn
C17H25N7O9 (471.17136800000003)
Ser His Asn Asp
C17H25N7O9 (471.17136800000003)
Ser Asn Asp His
C17H25N7O9 (471.17136800000003)
Ser Asn His Asp
C17H25N7O9 (471.17136800000003)
Val Cys His Asn
C18H29N7O6S (471.18999340000005)
Val Cys Asn His
C18H29N7O6S (471.18999340000005)
Val His Cys Asn
C18H29N7O6S (471.18999340000005)
Val His Asn Cys
C18H29N7O6S (471.18999340000005)
Val Asn Cys His
C18H29N7O6S (471.18999340000005)
Val Asn His Cys
C18H29N7O6S (471.18999340000005)
MK 886
C27H34ClNO2S (471.1998654000001)
Gloximonam
C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Dimethyl 3,3-({3-acetamido-4-[(E)-(4-nitrophenyl)diazenyl]phenyl }imino)dipropanoate (non-preferred name)
Dorsomorphin 2HCl
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclohexylamino)-2-oxoethyl]-7-methyl-N-(2-methylphenyl)- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclohexylamino)-2-oxoethyl]-7-methyl-N-(3-methylphenyl)- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclohexylamino)-2-oxoethyl]-7-methyl-N-(4-methylphenyl)- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,3-dimethylphenyl)-7-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,4-dimethylphenyl)-7-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,5-dimethylphenyl)-6-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,5-dimethylphenyl)-7-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2-ethylphenyl)-7-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(3,5-dimethylphenyl)-7-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(4-ethylphenyl)-6-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-N-(4-ethylphenyl)-7-methyl- (9CI)
C28H29N3O2S (471.19803740000003)
2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-5,12-dihydroquino[2,3-b]acridine-7,14-dione
Quetiapine sulfoxide (dihydrochloride)
C21H27Cl2N3O3S (471.11500920000003)
Quinacrine dihydrochloride
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
2,2-[[3-acetamido-4-[(4-nitrophenyl)azo]phenyl]imino]diethyl diacetate
methyl N-[3-(acetylamino)-4-[(4-nitrophenyl)azo]phenyl]-N-(3-methoxy-3-oxopropyl)-beta-alaninate
Muramic acid,N-acetyl-1-O-(phenylmethyl)-4,6-O-(phenylmethylene)- (9CI)
2-[[7-(acetylamino)-6-(benzyloxy)-2-phenylperhydropyrano[3,2-d][1,3]dioxin-8-yl]oxy]propanoic acid
2,3,5-Tri-O-benzoyl-beta-D-ribofuranosyl cyanide
C27H21NO7 (471.13179560000003)
Bms-641988
C20H20F3N3O5S (471.1075706000001)
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C146993 - Androgen Receptor Inhibitor C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen
LDS 751 dye
C25H30ClN3O4 (471.19247300000006)
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes
Platensimycin A3 Methyl Ester
A polycyclic cage that is the methyl ester derivative of 7-hydroxy substituted platensimycin. It is isolated from Streptomyces platensis.
N-[1-[4-(2-methoxyphenyl)-1-piperazinyl]-1-thiophen-2-ylpropan-2-yl]benzenesulfonamide
C24H29N3O3S2 (471.16502440000005)
4-(2-Hydroxybenzylamino)-N-(3-(4-fluorophenoxy)phenyl)piperidine-1-sulfonamide
C24H26FN3O4S (471.1627968000001)
N-((1R,2S)-2-(5-chloro-1H-indole-2-carboxamido)cyclohexyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide
C23H26ClN5O2S (471.1495646000001)
N-((1R,2R)-2-(5-Chloro-1H-indole-2-carboxamido)cyclohexyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-C]pyridine-2-carboxamide
C23H26ClN5O2S (471.1495646000001)
2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-YL)ethyl]-4-(4-ethoxy-1,1-biphenyl-4-YL)-4-oxobutanoic acid
Citrovorum factor
D020011 - Protective Agents > D000931 - Antidotes D018977 - Micronutrients > D014815 - Vitamins
2-[3a-[1-(furan-3-yl)-5,8a-dimethyl-3-oxo-4,6,7,8-tetrahydro-1H-isochromen-6-yl]-2,2-dimethyl-6-oxo-3,4,7,7a-tetrahydrofuro[3,2-c]pyran-3-yl]acetate
5-Formyltetrahydrofolate(2-)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
alpha-Neup5Ac-(2->6)-beta-D-Galp
alpha-Neup5Ac-(2->6)-D-Galp in which the anomeric configuration of the reducing-end D-galactose residue is beta.
alpha-Neu5Ac-(2->3)-D-Gal
An amino disaccharide consisting of D-galactose having an alpha-N-acetylneuraminyl residue attached at the 3-position
1-[(4-fluorophenyl)methyl]-4-(3,4,5-trimethoxyphenyl)-4H-pyridine-3,5-dicarboxylic acid dimethyl ester
C25H26FNO7 (471.16932180000003)
alpha-Neup5Ac-(2->6)-D-Galp
An amino disaccharide consisting of D-galactose having an alpha-N-acetylneuraminyl residue attached at the 6-position
N-[1-[4-(4-methylphenyl)-2-thiazolyl]-4-piperidinyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide
2-[[[4-cyclohexyl-5-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-5,6-dimethyl-3H-thieno[2,3-d]pyrimidin-4-one
2-[(6-methyl-1H-benzimidazol-2-yl)thio]-N-[3-(3,4,5,6-tetrahydro-2H-azepin-7-ylsulfamoyl)phenyl]acetamide
3-furanyl-[4-[3-(4-methoxyphenyl)-4-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]-1-piperazinyl]methanone
C23H20F3N5O3 (471.1518166000001)
3-ethyl-2-[(E)-2-[(E)-(3-ethyl-5,6-dimethyl-1,3-benzothiazol-2-ylidene)methyl]but-1-enyl]benzo[g][1,3]benzothiazol-3-ium
N-[4-(4-fluorophenyl)-2-thiazolyl]-3-methoxy-4-[2-(4-morpholinyl)-2-oxoethoxy]benzamide
C23H22FN3O5S (471.12641340000005)
3-[2,4-dioxo-1-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-quinazolinyl]-N-(2-furanylmethyl)propanamide
C25H21N5O5 (471.15426160000004)
Platensimycin A4 Methyl Ester
A polycyclic cage compound isolated from Streptomyces platensis.
Platensimycin A1 Methyl Ester
A polycyclic cage that is the methyl ester derivative of platensimycin A1. It is isolated from Streptomyces platensis.
Platensimycin A2 Methyl Ester
A polycyclic cage that is the methyl ester derivative of 11-hydroxy substituted platensimycin. It is isolated from Streptomyces platensis.
5-Oxo-2-pyrrolidinecarboxylic acid [2-[3-(4-methoxyphenyl)-5-(2-naphthalenyl)-3,4-dihydropyrazol-2-yl]-2-oxoethyl] ester
(4R,5R)-5-(2-azidophenyl)-2-[4-(3-hydroxypropoxy)phenyl]-4-(phenylmethyl)-5H-oxazole-4-carboxamide
3-O-{5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl}-alpha-D-galactopyranose
3-O-(5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranonosyl)-D-galactopyranose
2-[(2S,3S,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
C21H30FN3O6S (471.18392520000003)
N-[(5R,6S,9S)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
N-[(5R,6R,9S)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
2-[(2R,3R,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(3-morpholin-4-ylpropyl)acetamide
C21H30FN3O6S (471.18392520000003)
(2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(5R,6S,9R)-5-methoxy-8-(2-methoxyacetyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
N-[(5S,6R,9R)-5-methoxy-8-(2-methoxyacetyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
N-[(5S,6R,9S)-5-methoxy-8-(2-methoxyacetyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
2-[(2S,3R,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(3-morpholin-4-ylpropyl)acetamide
C21H30FN3O6S (471.18392520000003)
2-[(2R,3S,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
C21H30FN3O6S (471.18392520000003)
N-[(5R,6R,9R)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
N-[(5S,6S,9S)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
2-[(2S,3R,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
C21H30FN3O6S (471.18392520000003)
2-[(2R,3R,6R)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
C21H30FN3O6S (471.18392520000003)
N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
2-[(2R,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2R,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2S,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
[(1S)-7-methoxy-1-[(3-methoxyphenyl)methyl]-2-methylsulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C24H29N3O5S (471.18278240000006)
N-[(5S,6S,9R)-5-methoxy-8-(2-methoxy-1-oxoethyl)-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C21H33N3O7S (471.2039108000001)
2-[(2R,3S,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
C21H30FN3O6S (471.18392520000003)
2-[(2S,3S,6S)-3-[(2-fluorophenyl)sulfonylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide
C21H30FN3O6S (471.18392520000003)
N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]ethyl]-1,3-benzodioxole-5-carboxamide
2-[(2S,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2R,5S,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2S,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(2R,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide
(2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranose
5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-alpha-D-galacto-hexopyranose
2-amino-4-({2-[(1-carboxy-2-hydroxy-2-phenylethyl)sulfanyl]-1-[(carboxymethyl)-C-hydroxycarbonimidoyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C19H25N3O9S (471.13114400000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1,3-dihydroxy-2-methyl-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H29N3O8S (471.16752740000004)
(2R,4S,5R,6R)-5-acetamido-2-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
disodium;(2R)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
C20H19N5Na2O6 (471.11306740000003)
(6S)-5-formyltetrahydrofolate(2-)
A dicarboxylic acid dianion arising from deprotonation of both carboxylic acid groups of (6S)-5-formyltetrahydrofolic acid.
MK886
C27H34ClNO2S (471.1998654000001)
D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors
5-Formyltetrahydrofolate(2-)
A dicarboxylic acid dianion obtained by deprotonation of the carboxy groups of 5-formyltetrahydrofolic acid.
10-Formyltetrahydrofolic acid
A form of tetrahydrofolate that acts as a donor of formyl groups in anabolism. In these reactions 10-formyltetrahydrofolic acid is used as a substrate in formyltransferase reactions, which is important in purine biosynthesis.
alpha-Neup5Ac-(2->3)-beta-D-Galp
An amino disaccharide consisting of beta-D-galactose having an alpha-N-acetylneuraminyl residue attached at the 3-position
alpha-Neup5Ac-(2->3)-alpha-D-GalpNAc
An amino disaccharide comprised of an N-acetyl-alpha-neuraminyl residue linked (2->3) to N-acetyl-alpha-D-galactosamine
10-formyltetrahydrofolate(2-)
Dianion of 10-formyltetrahydrofolic acid arising from deprotonation of both carboxylic acid functions.
BI-6C9
BI-6C9 is a highly specific BH3 interacting domain (Bid) inhibitor, which prevents mitochondrial outer membrane potential (MOMP) and mitochondrial fission, and protects the cells from mitochondrial apoptosis inducing factor (AIF) release and caspase-independent cell death in neurons[1].
Z-Gly-Arg-Thiobenzyl ester
C23H29N5O4S (471.19401540000007)
Z-Gly-Arg-Thiobenzyl ester is a chromogenic substrate for plasmogen-activated serine proteases[1].
n-[2,6-dihydroxy-3-(methoxycarbonyl)phenyl]-3-{10-hydroxy-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl}propanimidic acid
methyl 2-{8-[4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]-9-hydroxy-1-methyl-5,10-dioxo-3h-benzo[g]isochromen-3-yl}acetate
(1s,3s,12r,14r,27s)-3-[(2s)-butan-2-yl]-12,26-dihydroxy-2,5,15,23,25-pentaazaheptacyclo[12.10.2.1²,⁵.0⁶,¹¹.0¹⁵,²⁴.0¹⁷,²².0¹²,²⁷]heptacosa-6,8,10,17,19,21,23,25-octaene-4,16-dione
aristolactam-n-β-d-glucoside
{"Ingredient_id": "HBIN016784","Ingredient_name": "aristolactam-n-\u03b2-d-glucoside","Alias": "NA","Ingredient_formula": "C23H21NO10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1697","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(15r,16r,17s,18r,20s)-2,15,16-trihydroxy-8-[(1r)-1-hydroxypropyl]-17-methoxy-6,18-dimethyl-19,21-dioxa-7-azapentacyclo[12.7.0.0³,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-1(14),2,4(9),5,7,11-hexaene-10,13-dione
12,26-dihydroxy-3-(sec-butyl)-2,5,15,23,25-pentaazaheptacyclo[12.10.2.1²,⁵.0⁶,¹¹.0¹⁵,²⁴.0¹⁷,²².0¹²,²⁷]heptacosa-6,8,10,17,19,21,23,25-octaene-4,16-dione
15-benzyl-13-ethyl-3,11-dihydroxy-16-oxa-2,10,13-triazatricyclo[16.4.0.0⁴,⁹]docosa-1(22),2,4,6,8,10,18,20-octaene-14,17-dione
n-[2,6-dihydroxy-3-(methoxycarbonyl)phenyl]-3-[(1r,5s,6r,7s,9s,11r)-11-hydroxy-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl]propanimidic acid
n-[2,6-dihydroxy-3-(methoxycarbonyl)phenyl]-3-[(1s,5s,6r,7s,9s,10r)-10-hydroxy-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl]propanimidic acid
2-{[2-(3,5-dihydroxyphenyl)-8-hydroxy-3,5,7-trimethyl-6,10-dioxooxecan-4-yl]amino}benzoic acid
n-{[(2r,3s,4r,5s)-5-(2,4-dihydroxypyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-2-{[1-hydroxy-2-(c-hydroxycarbonimidoylamino)ethylidene]amino}pentanediimidic acid
C17H25N7O9 (471.17136800000003)
n-[2,6-dihydroxy-3-(methoxycarbonyl)phenyl]-3-[(1s,5s,6r,7s,9s)-9-(hydroxymethyl)-5-methyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl]propanimidic acid
2-{[4-carboxy-4-({2-[(2-carboxyphenyl)-c-hydroxycarbonimidoyl]-1-hydroxyethylidene}amino)-1-hydroxybutylidene]amino}benzoic acid
C22H21N3O9 (471.12777360000007)